Colorectal cancer and evidence for cure by adjuvant chemotherapy

Joleen M Hubbard, Daniel Sargent

Research output: Contribution to journalArticle

Abstract

Future database analyses will demonstrate how the results of this study compare with current management of adjuvant colon cancer. With the addition of oxaliplatin to 5-FU/LV as the standard of care in the adjuvant colon cancer setting, there has been a 7% improvement in the 3-year DFS of these patients,1 which has been shown to provide an OS survival benefit after 6 years.10 Based on the results of this analysis, the OS benefit from oxaliplatin is likely to grow with time since few late recurrences are anticipated. It is unclear if findings will be similar with biologic therapies, which are currently being tested in clinical trials for adjuvant colon cancer. If biologic therapy prevents recurrences, then findings of this analysis will likely hold true. However, results may not be similar if recurrences are simply delayed by biologic agents. Large database analyses provide a greater understanding of the nature of disease and response to therapy, as well as guidance for the conduct of clinical trials and the appropriateness of statistical models. The ACCENT collaborators will continue to obtain individual patient data from the latest generation of adjuvant colon cancer therapy clinical trials.

Original languageEnglish (US)
JournalAmerican Journal of Hematology/ Oncology
Volume8
Issue number9
StatePublished - Sep 2009

Fingerprint

oxaliplatin
Adjuvant Chemotherapy
Colonic Neoplasms
Colorectal Neoplasms
Biological Therapy
Clinical Trials
Recurrence
Databases
Biological Factors
Statistical Models
Standard of Care
Fluorouracil
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Colorectal cancer and evidence for cure by adjuvant chemotherapy. / Hubbard, Joleen M; Sargent, Daniel.

In: American Journal of Hematology/ Oncology, Vol. 8, No. 9, 09.2009.

Research output: Contribution to journalArticle

@article{a7cfd80c49bc43a2874330a356ecdf96,
title = "Colorectal cancer and evidence for cure by adjuvant chemotherapy",
abstract = "Future database analyses will demonstrate how the results of this study compare with current management of adjuvant colon cancer. With the addition of oxaliplatin to 5-FU/LV as the standard of care in the adjuvant colon cancer setting, there has been a 7{\%} improvement in the 3-year DFS of these patients,1 which has been shown to provide an OS survival benefit after 6 years.10 Based on the results of this analysis, the OS benefit from oxaliplatin is likely to grow with time since few late recurrences are anticipated. It is unclear if findings will be similar with biologic therapies, which are currently being tested in clinical trials for adjuvant colon cancer. If biologic therapy prevents recurrences, then findings of this analysis will likely hold true. However, results may not be similar if recurrences are simply delayed by biologic agents. Large database analyses provide a greater understanding of the nature of disease and response to therapy, as well as guidance for the conduct of clinical trials and the appropriateness of statistical models. The ACCENT collaborators will continue to obtain individual patient data from the latest generation of adjuvant colon cancer therapy clinical trials.",
author = "Hubbard, {Joleen M} and Daniel Sargent",
year = "2009",
month = "9",
language = "English (US)",
volume = "8",
journal = "American Journal of Hematology/ Oncology",
issn = "1542-9520",
publisher = "TyWin Communications",
number = "9",

}

TY - JOUR

T1 - Colorectal cancer and evidence for cure by adjuvant chemotherapy

AU - Hubbard, Joleen M

AU - Sargent, Daniel

PY - 2009/9

Y1 - 2009/9

N2 - Future database analyses will demonstrate how the results of this study compare with current management of adjuvant colon cancer. With the addition of oxaliplatin to 5-FU/LV as the standard of care in the adjuvant colon cancer setting, there has been a 7% improvement in the 3-year DFS of these patients,1 which has been shown to provide an OS survival benefit after 6 years.10 Based on the results of this analysis, the OS benefit from oxaliplatin is likely to grow with time since few late recurrences are anticipated. It is unclear if findings will be similar with biologic therapies, which are currently being tested in clinical trials for adjuvant colon cancer. If biologic therapy prevents recurrences, then findings of this analysis will likely hold true. However, results may not be similar if recurrences are simply delayed by biologic agents. Large database analyses provide a greater understanding of the nature of disease and response to therapy, as well as guidance for the conduct of clinical trials and the appropriateness of statistical models. The ACCENT collaborators will continue to obtain individual patient data from the latest generation of adjuvant colon cancer therapy clinical trials.

AB - Future database analyses will demonstrate how the results of this study compare with current management of adjuvant colon cancer. With the addition of oxaliplatin to 5-FU/LV as the standard of care in the adjuvant colon cancer setting, there has been a 7% improvement in the 3-year DFS of these patients,1 which has been shown to provide an OS survival benefit after 6 years.10 Based on the results of this analysis, the OS benefit from oxaliplatin is likely to grow with time since few late recurrences are anticipated. It is unclear if findings will be similar with biologic therapies, which are currently being tested in clinical trials for adjuvant colon cancer. If biologic therapy prevents recurrences, then findings of this analysis will likely hold true. However, results may not be similar if recurrences are simply delayed by biologic agents. Large database analyses provide a greater understanding of the nature of disease and response to therapy, as well as guidance for the conduct of clinical trials and the appropriateness of statistical models. The ACCENT collaborators will continue to obtain individual patient data from the latest generation of adjuvant colon cancer therapy clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=73649138909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649138909&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:73649138909

VL - 8

JO - American Journal of Hematology/ Oncology

JF - American Journal of Hematology/ Oncology

SN - 1542-9520

IS - 9

ER -